GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development.

The inability to concentrate therapeutic antibodies in the brain has long dogged drug makers, particularly in Alzheimer’s disease, where insufficient levels of anti-β amyloid antibodies is proposed as one cause of their failure to clear senile plaques...